Skip to content

Effect of Propofol Cardioplegia Solution on Myocardial Injury Bio marker

Effect of Propofol Cardioplegia Solution on Myocardial Injury Bio marker in Coronary Artery Bypass Grafting Surgery

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20180922041084N2
Enrollment
120
Registered
2019-01-06
Start date
2019-02-26
Completion date
Unknown
Last updated
2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerosis. Atherosclerotic heart disease

Interventions

Intervention 1: Intervention group:Patients in the intervention group received 1200 µg / min propofol by syringe pump as a cardioplegic solution. Intervention 2: Control group: Patients in the contro

Sponsors

Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patient who are candidate for elective Coronary Artery Bypass surgery

Exclusion criteria

Exclusion criteria: Redo surgery Primary troponin level is above 3 µg / L sever Renal failure sever Liver failure congestive Heart Failure grade IV Ejection fraction lower than 30% Allergy to eggs, soy, peanuts

Design outcomes

Primary

MeasureTime frame
Serum level of troponin I. Timepoint: 1st sample just after induction ,2nd sample just after chest closure , 3rd sample 6 hours after arrival to ICU and last sample 24 hours after arrival to the ICU. Method of measurement: Lab test.;Serum level of CPKMB. Timepoint: 1st sample just after induction ,2nd sample just after chest closure , 3rd sample 6 hours after arrival to ICU and last sample 24 hours after arrival to the ICU. Method of measurement: Lab test.

Secondary

MeasureTime frame
Arhytmia. Timepoint: During operation and after that. Method of measurement: Monitoring.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholam Ali Heidari kochi

Shiraz University of Medical Sciences

drtabib.maryam@yahoo.com+98 71 3647 4270

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026